Core Points - The company announced the resignation of its Vice President, Wu Huafeng, due to personal reasons [1] - Wu Huafeng will not hold any other positions within the company after his resignation [1]

Group 1 - The board of directors of Shanghai Xuantai Pharmaceutical Technology Co., Ltd. received a resignation letter from Deputy General Manager Wu Huafeng on September 30, 2025, citing personal reasons for his departure [1] - After resigning, Wu Huafeng will no longer hold any other positions within the company [1] Group 2 - There is a growing concern in the industry regarding consumer loans, as banks are now demanding invoices to be uploaded within seven days, leading to anxiety among some individuals while others are finding ways to profit from this situation by offering invoice services [1]

国泰海通证券股份有限公司 关于上海宣泰医药科技股份有限公司增加 2025 年度日常关 联交易预计额度的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为上 海宣泰医药科技股份有限公司（以下简称"宣泰医药"或"公司"）首次公开发行 股票并上市保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交 易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第1 号——规范运作》等有关规定，对宣泰医药2025年度日常关联交易预计额度 相关事项进行了审慎核查，具体情况如下： 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 公司于2025年2月19日召开第二届董事会第十四次会议、第二届监事会第十 次会议，审议通过了《关于公司2025年度日常关联交易预计的议案》，具体内 容详见公司2025年2月20日于上海证券交易所网站（www.sse.com.cn）披露的《 关于2025年度日常关联交易预计的公告》（公告编号：2025-006）。 公司于2025年9月30日召开第二届董事会第十九次会议，审议通过了《关于 增加2025年度日常关联交易预计额度的议案》，关联董事沈思宇、MA ...

证券代码：688247 证券简称：宣泰医药 公告编号：2025-039 上海宣泰医药科技股份有限公司 关于增加 2025 年度日常关联交易预计额度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 公司于 2025 年 2 月 19 日召开第二届董事会第十四次会议、第二届监事会第 十次会议，审议通过了《关于公司 2025 年度日常关联交易预计的议案》，具体内 容详见公司 2025 年 2 月 20 日于上海证券交易所网站（www.sse.com.cn）披露的 《关于 2025 年度日常关联交易预计的公告》（公告编号：2025-006）。 结合公司业务发展及生产经营情况，公司本次增加 2025 年度日常关联交易预计额度情况如下： 公司于 2025 年 9 月 30 日召开第二届董事会第十九次会议，审议通过了《关 于增加 2025 年度日常关联交易预计额度的议案》，关联董事沈思宇、MAOJIAN GU 已回避表决，出席会议的非关联董事一致同意该议案 ...

证券代码：688247 证券简称：宣泰医药 公告编号：2025-038 上海宣泰医药科技股份有限公司 关于公司高级管理人员离任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 上海宣泰医药科技股份有限公司（以下简称"公司"）董事会于 2025 年 9 月 30 日收到副总经理吴华峰先生递交的书面辞职报告。吴华峰先生因个人原因， 申请辞去公司副总经理职务，辞任后将不再担任公司其他任何职务。 截至本公告披露日，吴华峰先生未直接持有公司股份,不存在应当履行而未 履行的承诺事项。 吴华峰先生在担任公司副总经理期间恪尽职守，勤勉尽责，公司及董事会对 吴华峰先生在任职期间所作的贡献表示衷心感谢！ 一、高级管理人员离任情况 (一) 提前离任的基本情况 | | | | | | | | 是否继续在上 | | 是否存在 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 姓名 | 离任职务 | 离任时间 | | 原定任期 到期日 | | 离任原因 ...

Core Points - The Vice President of Shanghai Xuantai Pharmaceutical Technology Co., Ltd., Wu Huafeng, submitted a written resignation due to personal reasons [1] - Wu Huafeng's term was originally set to end on May 30, 2026, and after his resignation, he will no longer hold any position within the company [1] - The resignation took effect upon delivery to the board of directors, and the company has ensured that the transition will not affect its normal operations and management [1]

Core Viewpoint - Shanghai Xuantai Pharmaceutical Technology Co., Ltd. announced that its wholly-owned subsidiary, Jiangsu Xuantai Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for a supplemental application to increase the specification of its drug, Saxagliptin Metformin Extended-Release Tablets, to include a new dosage of 50mg Saxagliptin and 500mg Metformin per tablet [1][2]. Drug Basic Information - Drug Name: Saxagliptin Metformin Extended-Release Tablets [1] - Registration Category: Chemical Drug [1] - Application Matter: Addition of specification "each tablet contains 50mg Saxagliptin and 500mg Metformin" [1] - Drug Approval Number: Guoyao Zhunzi H20258134 [1] - Dosage Form: Tablet [1] - Specification: Each tablet contains 50mg Saxagliptin and 500mg Metformin [1] - Marketing Authorization Holder: Jiangsu Xuantai Pharmaceutical Co., Ltd. [1] - Approval Conclusion: The application meets the requirements for drug registration and a new drug approval number has been issued [1]. Other Relevant Information - Saxagliptin Metformin Extended-Release Tablets are indicated for adult patients with type 2 diabetes who are currently receiving combined treatment with Saxagliptin and Metformin Extended-Release Tablets [2]. - The drug was developed by Merck Sharp & Dohme and was first approved for marketing in the United States in February 2012 [2]. - It was first approved for sale in China in May 2023 and is classified as a Category B product under medical insurance [2]. Impact on the Company - The newly approved specification of 50mg Saxagliptin and 500mg Metformin per tablet is expected to better meet patient medication needs, enhance the company's product competitiveness, and increase market share [3]. - The specific sales performance of the product may be influenced by various factors such as market environment and channel expansion, which introduces uncertainty [3].

Group 1 - Dongxing Medical plans to acquire 90% equity of Wuhan Yijiaobao for cash, which is expected to constitute a major asset restructuring [1] - Fosun Pharma's subsidiary plans to transfer 100% equity of Shanghai Cloning, with a transaction value of up to 1.256 billion yuan [1] Group 2 - *ST Songfa's subsidiary signed a shipbuilding contract worth approximately 400-600 million USD for four VLCCs, expected delivery between late 2026 and mid-2027 [3] - Qibin Group obtained financing support of up to 90 million yuan for share repurchase [4] Group 3 - Shapuaisi's shareholder plans to reduce holdings by up to 3% of the company's total shares [5] - *ST Kaixin intends to use up to 310 million yuan for cash management in safe and liquid financial products [6] Group 4 - Junchen Technology's shareholders plan to transfer 2.5% of the company's shares due to personal funding needs [7] - Jingliang Holdings received an administrative regulatory measure from Hainan Securities Regulatory Bureau for improper revenue recognition involving 299 million yuan [7] Group 5 - Tongcheng Holdings received a cash dividend of 24.6643 million yuan from Changsha Bank [9] - Shenyang Chemical appointed Chen Liguo as the new general manager [10] Group 6 - Huaguang Huaneng signed a contract for a 160 million yuan waste heat boiler project [15] - Shuxian Valley's subsidiary completed the re-registration of a health food product [16] Group 7 - Xuanta Pharmaceutical's new specification for a diabetes treatment drug was approved [17] - Panlong Pharmaceutical's application for a pain relief gel patch was accepted by the drug regulatory authority [18] Group 8 - Zhiguang Electric's subsidiary won a procurement contract worth 164 million yuan for a storage system [19] - Chitianhua's production facility resumed operations after maintenance [20] Group 9 - Haitong Development's application for a specific A-share issuance was accepted by the Shanghai Stock Exchange, aiming to raise 210 million yuan [20] - Risheng Technology's shareholders plan to transfer 4.02% of the company's shares [33] Group 10 - Pingmei Shares' controlling shareholder plans a strategic restructuring with Henan Energy Group [35] - Shenghui Integration's controlling shareholder committed not to reduce shareholdings for 12 months [37] Group 11 - Agricultural Bank and Bank of China will no longer establish supervisory boards, with their functions transferred to the audit committees [39][40] - Dongfang Yuhong's subsidiary signed a contract for a seawater pipeline project worth 2.524 billion USD [40][41] Group 12 - Ganfeng Lithium plans to introduce investors for a capital increase of up to 2.5 billion yuan [50] - Hanyu Pharmaceutical intends to raise up to 968 million yuan for various projects [51]

证券代码：688247 证券简称：宣泰医药 公告编号：2025-037 上海宣泰医药科技股份有限公司 自愿披露关于西格列汀二甲双胍缓释片新增规格 获得国家药品监督管理局批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 6、规格：每片含磷酸西格列汀 50mg（以 C₁₆H₁₅F₆N₅O 计）和盐酸二甲双 胍 500mg 7、上市许可持有人：江苏宣泰药业有限公司 8、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品此次申请事项符合药品注册的有关要求，批准本品增加"每片含磷酸西格列 汀 50mg（以 C₁₆H₁₅F₆N₅O 计）和盐酸二甲双胍 500mg"规格，核发新的药品批 准文号。 近日，上海宣泰医药科技股份有限公司（以下简称"公司"）全资子公司江 苏宣泰药业有限公司收到国家药品监督管理局（以下简称"国家药监局"）核准 签发的《药品补充申请批准通知书》，西格列汀二甲双胍缓释片增加"每片含磷 西格列汀 50mg（以 C₁₆H₁₅F₆N₅O 计）和盐酸二甲双胍 500mg"规格的补充申请 已获得国家 ...

Core Viewpoint - The company announced that its wholly-owned subsidiary, Jiangsu Xuantai Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for a supplemental application regarding the extended-release tablets of Sitagliptin and Metformin [1] Group 1 - The approved supplemental application includes a new specification of "each tablet contains 50mg of Sitagliptin and 500mg of Metformin" [1] - The extended-release tablets are intended for adult patients with type 2 diabetes who are currently receiving a combination treatment of Sitagliptin and Metformin [1]